InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a report released on Friday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital assumed coverage on InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price objective for the company.

InspireMD Price Performance

Shares of InspireMD stock opened at $2.86 on Friday. The stock has a market capitalization of $74.60 million, a price-to-earnings ratio of -3.81 and a beta of 1.00. The business has a 50-day moving average of $2.79 and a 200 day moving average of $2.74. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42.

InspireMD (NYSE:NSPR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same quarter in the prior year, the business earned ($0.15) EPS. Equities research analysts anticipate that InspireMD will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On InspireMD

A number of hedge funds have recently bought and sold shares of the business. Affiance Financial LLC lifted its holdings in shares of InspireMD by 2.9% in the 4th quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after purchasing an additional 5,376 shares during the last quarter. Parkman Healthcare Partners LLC bought a new stake in InspireMD in the third quarter valued at $279,000. Essex Investment Management Co. LLC acquired a new position in shares of InspireMD during the fourth quarter valued at $191,000. Legato Capital Management LLC acquired a new position in shares of InspireMD during the fourth quarter valued at $47,000. Finally, Renaissance Technologies LLC bought a new position in shares of InspireMD during the fourth quarter worth about $27,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.